Cargando…

Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has resulted in infections among patients with cancer. Our study aimed to investigate the potential adverse impact of anti-cancer treatments within 2 weeks of COVID-19 infection on clinical outcomes in patients with cancer. METHODS: This r...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jia-Xin, Liu, Bo, Cong, Xiao-Feng, Guan, Yan-Jie, Zhang, Yi-Qun, Song, Wei, Li, Zhi, Liu, Zi-Ling, Wang, Nan-Ya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478212/
https://www.ncbi.nlm.nih.gov/pubmed/37675234
http://dx.doi.org/10.3389/fonc.2023.1193082
_version_ 1785101297585750016
author Huang, Jia-Xin
Liu, Bo
Cong, Xiao-Feng
Guan, Yan-Jie
Zhang, Yi-Qun
Song, Wei
Li, Zhi
Liu, Zi-Ling
Wang, Nan-Ya
author_facet Huang, Jia-Xin
Liu, Bo
Cong, Xiao-Feng
Guan, Yan-Jie
Zhang, Yi-Qun
Song, Wei
Li, Zhi
Liu, Zi-Ling
Wang, Nan-Ya
author_sort Huang, Jia-Xin
collection PubMed
description BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has resulted in infections among patients with cancer. Our study aimed to investigate the potential adverse impact of anti-cancer treatments within 2 weeks of COVID-19 infection on clinical outcomes in patients with cancer. METHODS: This retrospective cohort study analyzed 70 cancer patients with COVID-19 infection from the First Hospital of Jilin University in Changchun City, Jilin Province, between March and June 2022. Data on demographic characteristics, vaccination status, COVID-19 clinical classification, symptoms, complications, tumor-related characteristics, laboratory examinations and medical interventions were extracted from electronic medical record. The primary outcome of our study was Intensive Care Unit (ICU) admission. Logistic regression model was performed to investigate the association between anti-cancer treatments within 2 weeks after COVID-19 infection and the risk of ICU admission. RESULTS: Of the 70 patients enrolled in this study, 37 received anti-cancer treatments within 2 weeks after COVID-19 infection. Patients receiving anti-cancer treatment were more likely to experience non-mild COVID-19, require oxygen therapy, develop acute respiratory distress syndrome (ARDS) and exhibit elevated inflammatory levels. The risk of ICU admission (P<0.001) and 30-day mortality after reverse transcriptase polymerase chain reaction (RT-PCR) negative conversion (P=0.007) was significantly higher in patients receiving anti-cancer treatments. In multivariate Logistic regression analysis, non-mild classification of COVID-19, anti-cancer treatments within 2 weeks and ECOG > 1were all independently associated with ICU admission after adjusting for confounder factors. The risk of ICU admission rose to 43.63 times (95% confidence interval=1.31–1452.94, P=0.035) in patients receiving anti-cancer treatments within 2 weeks. CONCLUSION: Anti-cancer treatments within 2 weeks of COVID-19 infection increase the risk of ICU admission and 30-day mortality after RT-PCR negative conversion in patients with cancer. It may be recommended to postpone cancer-related treatments for more than 2 weeks in cancer patients with COVID-19 infection.
format Online
Article
Text
id pubmed-10478212
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104782122023-09-06 Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19 Huang, Jia-Xin Liu, Bo Cong, Xiao-Feng Guan, Yan-Jie Zhang, Yi-Qun Song, Wei Li, Zhi Liu, Zi-Ling Wang, Nan-Ya Front Oncol Oncology BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has resulted in infections among patients with cancer. Our study aimed to investigate the potential adverse impact of anti-cancer treatments within 2 weeks of COVID-19 infection on clinical outcomes in patients with cancer. METHODS: This retrospective cohort study analyzed 70 cancer patients with COVID-19 infection from the First Hospital of Jilin University in Changchun City, Jilin Province, between March and June 2022. Data on demographic characteristics, vaccination status, COVID-19 clinical classification, symptoms, complications, tumor-related characteristics, laboratory examinations and medical interventions were extracted from electronic medical record. The primary outcome of our study was Intensive Care Unit (ICU) admission. Logistic regression model was performed to investigate the association between anti-cancer treatments within 2 weeks after COVID-19 infection and the risk of ICU admission. RESULTS: Of the 70 patients enrolled in this study, 37 received anti-cancer treatments within 2 weeks after COVID-19 infection. Patients receiving anti-cancer treatment were more likely to experience non-mild COVID-19, require oxygen therapy, develop acute respiratory distress syndrome (ARDS) and exhibit elevated inflammatory levels. The risk of ICU admission (P<0.001) and 30-day mortality after reverse transcriptase polymerase chain reaction (RT-PCR) negative conversion (P=0.007) was significantly higher in patients receiving anti-cancer treatments. In multivariate Logistic regression analysis, non-mild classification of COVID-19, anti-cancer treatments within 2 weeks and ECOG > 1were all independently associated with ICU admission after adjusting for confounder factors. The risk of ICU admission rose to 43.63 times (95% confidence interval=1.31–1452.94, P=0.035) in patients receiving anti-cancer treatments within 2 weeks. CONCLUSION: Anti-cancer treatments within 2 weeks of COVID-19 infection increase the risk of ICU admission and 30-day mortality after RT-PCR negative conversion in patients with cancer. It may be recommended to postpone cancer-related treatments for more than 2 weeks in cancer patients with COVID-19 infection. Frontiers Media S.A. 2023-08-22 /pmc/articles/PMC10478212/ /pubmed/37675234 http://dx.doi.org/10.3389/fonc.2023.1193082 Text en Copyright © 2023 Huang, Liu, Cong, Guan, Zhang, Song, Li, Liu and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Huang, Jia-Xin
Liu, Bo
Cong, Xiao-Feng
Guan, Yan-Jie
Zhang, Yi-Qun
Song, Wei
Li, Zhi
Liu, Zi-Ling
Wang, Nan-Ya
Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19
title Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19
title_full Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19
title_fullStr Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19
title_full_unstemmed Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19
title_short Anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with COVID-19
title_sort anti-cancer treatment within two weeks serves as a risk factor for clinical outcomes among cancer patients with covid-19
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478212/
https://www.ncbi.nlm.nih.gov/pubmed/37675234
http://dx.doi.org/10.3389/fonc.2023.1193082
work_keys_str_mv AT huangjiaxin anticancertreatmentwithintwoweeksservesasariskfactorforclinicaloutcomesamongcancerpatientswithcovid19
AT liubo anticancertreatmentwithintwoweeksservesasariskfactorforclinicaloutcomesamongcancerpatientswithcovid19
AT congxiaofeng anticancertreatmentwithintwoweeksservesasariskfactorforclinicaloutcomesamongcancerpatientswithcovid19
AT guanyanjie anticancertreatmentwithintwoweeksservesasariskfactorforclinicaloutcomesamongcancerpatientswithcovid19
AT zhangyiqun anticancertreatmentwithintwoweeksservesasariskfactorforclinicaloutcomesamongcancerpatientswithcovid19
AT songwei anticancertreatmentwithintwoweeksservesasariskfactorforclinicaloutcomesamongcancerpatientswithcovid19
AT lizhi anticancertreatmentwithintwoweeksservesasariskfactorforclinicaloutcomesamongcancerpatientswithcovid19
AT liuziling anticancertreatmentwithintwoweeksservesasariskfactorforclinicaloutcomesamongcancerpatientswithcovid19
AT wangnanya anticancertreatmentwithintwoweeksservesasariskfactorforclinicaloutcomesamongcancerpatientswithcovid19